Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Wimolnut Manheng
Observed name:
Manheng, Wimolnut
Institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
Observed institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research,
Virginia Commonwealth University,
Virginia Commonwealth University Medical Center
ORCID:
0000-0003-3909-086X
Observed ORCID:
0000-0003-3909-086X
OpenAlex ID:
A5068416130
FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy
2018
·
Gwynn Ison
, Lynn J. Howie
, et al.
·
Clinical Cancer Research
·
145
FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer
2023
·
Asma Dilawari
, Mirat Shah
, et al.
·
Clinical Cancer Research
·
142
PDF
Investigation of sex-based differences in the immunotoxicity of silver nanoparticles
2024
·
Brandon Canup
, Paul Rogers
, et al.
·
Nanotoxicology
·
11
PDF
FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA -Mutated Metastatic Castration-Resistant Prostate Cancer
2025
·
William F. Maguire
, Dow-Chung Chi
, et al.
·
Clinical Cancer Research
·
5
Evaluation of skin sensitization induced by four ionic liquids
2021
·
Rachel P. Frawley
, Dori R. Germolec
, et al.
·
Journal of Applied Toxicology
·
4
Evaluation of 2-methoxy-4-nitroaniline (MNA) in hypersensitivity, 14-day subacute, reproductive, and genotoxicity studies
2020
·
Rachel P. Frawley
, Kristine L. Witt
, et al.
·
Toxicology
·
4
Supplementary Table S1 from FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
2025
·
William F. Maguire
, Dow-Chung Chi
, et al.
PDF
Data from FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
2025
·
William F. Maguire
, Dow-Chung Chi
, et al.
Supplementary Table S3 from FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
2025
·
William F. Maguire
, Dow-Chung Chi
, et al.
PDF
Supplementary Table S2 from FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
2025
·
William F. Maguire
, Dow-Chung Chi
, et al.
PDF
Show more works
View as search
Works count:
11
Citation count:
311
H-index:
4
I10-index:
3
Year
Topic
Type